Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | INSR | P06213 | 3/20 | 0.43 |
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.43 |
| ▸ | LTK | P29376 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MERTK | Q12866 | 3/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660844 | 1.00 | AKT1 (0.55) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4722256 | 0.91 | AKT1 (0.54) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4722252 | 0.91 | AKT1 (0.54) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4658638 | 0.88 | AKT1 (0.48) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4658629 | 0.88 | AKT1 (0.48) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4658758 | 0.86 | AKT1 (0.56) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4659698 | 0.86 | AKT1 (0.50) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4659705 | 0.86 | AKT1 (0.50) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4658755 | 0.86 | AKT1 (0.56) | AKT1ROCK1FGFR1FGFR2FGFR3 | |
| SCHEMBL4791666 | 0.85 | AKT1 (0.56) | AKT1ROCK1FGFR1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | AKT1 1/4885ROCK1 589/4885FGFR1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.